Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacillus Infections Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Completed No phase listed Observational

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

NCT00050310
View directory record Official record
Conditions
Anthrax, Bacillus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Anthrax-rPA: Safety, Tolerability, Immunogenicity

NCT00063843
View directory record Official record
Conditions
Anthrax
Interventions
Recombinant Protective Antigen, Anthrax Vaccine Adsorbed
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

NCT00170469
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
AVA, rPA vaccine containing alhydrogel
Biological
Lead sponsor
PharmAthene UK Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
16
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

NCT01597973
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection
Interventions
colistin and meropenem, colistin and placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 95 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
6
States / cities
Miami, Florida • Detroit, Michigan • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 2, 2026, 5:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

NCT05606159
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Bacillus velezensis DSM 33864, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

BCG Vaccine for Health Care Workers as Defense Against COVID 19

NCT04348370
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Interventions
BCG Vaccine, Placebo Vaccine
Biological
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 75 Years
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Bryan, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT04067011
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
Drug · Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
DeLand, Florida • Kansas City, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG strain Connaught, BCG strain Danish, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

UMD rPA Regimen Trial in Adults

NCT00133484
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 2, 2026, 5:41 AM EDT
Completed No phase listed Observational

Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn

NCT02653157
View directory record Official record
Conditions
Multi-drug Resistant Gram-negative Bacilli Colonization
Interventions
MDR-GNB
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

NCT00109655
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Neoplasms
Interventions
Oncolytic adenovirus (serotype 5) - CG0070
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Sep 2, 2026, 5:41 AM EDT
Completed No phase listed Observational

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362
View directory record Official record
Conditions
Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 2, 2026, 5:41 AM EDT
Completed No phase listed Observational

Febrile Whole Blood Specimen Collection and Testing

NCT03498027
View directory record Official record
Conditions
Febrile Infection, Anthrax
Interventions
TaqMan Bacillus anthracis Detection Kit
Device
Lead sponsor
MRI Global
Industry
Eligibility
2 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Not applicable Interventional

Probiotics Pilot Project

NCT04247854
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Bacillus subtilis probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
View directory record Official record
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 31 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 5:41 AM EDT